학술논문
Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
Document Type
Article
Author
Rojas Rojas, Teresa; Poizot-Martin, Isabelle; Rey, David; Duvivier, Claudine; Bani-Sadr, Firouzé; Cabie, André; Delobel, Pierre; Jacomet, Christine; Allavena, Clotilde; Ferry, Tristan; Pugliese, Pascal; Valantin, Marc-Antoine; Lamaury, Isabelle; Hustache-Matthieu, Laurent; Fresard, Anne; Houyou, Tamazighth; Huleux, Thomas; Cheret, Antoine; Makinson, Alain; Obry-Roguet, Véronique
Source
Subject
*HIV infection transmission
*HIV-positive persons
*COLORECTAL cancer
*BREAST cancer
*HIV infections
*CD4 lymphocyte count
*PANEL analysis
*
*
*
*
*
*
Language
ISSN
1932-6203
Abstract
Background: We aimed to evaluate the incidence rates between 2010 and 2015 for invasive cervical cancer (ICC), breast cancer (BC), and colorectal cancer (CRC) in people living with HIV (PLWH) in France, and to compare them with those in the French general population. These cancers are targeted by the national cancer-screening program. Setting: This is a retrospective study based on the longitudinal data of the French Dat'AIDS cohort. Methods: Standardized incidence ratios (SIR) for ICC and BC, and incidence rates for all three cancers were calculated overall and for specific sub-populations according to nadir CD4 cell count, HIV transmission category, HIV diagnosis period, and HCV coinfection. Results: The 2010–2015 CRC incidence rate was 25.0 [95% confidence interval (CI): 18.6–33.4] per 100,000 person-years, in 44,642 PLWH (both men and women). Compared with the general population, the ICC incidence rate was significantly higher in HIV-infected women both overall (SIR = 1.93, 95% CI: 1.18–3.14) and in the following sub-populations: nadir CD4 ≤ 200 cells/mm3 (SIR = 2.62, 95% CI: 1.45–4.74), HIV transmission through intravenous drug use (SIR = 5.14, 95% CI: 1.93–13.70), HCV coinfection (SIR = 3.52, 95% CI: 1.47–8.47) and HIV diagnosis before 2000 (SIR = 2.06, 95% CI: 1.07–3.97). Conversely, the BC incidence rate was significantly lower in the study sample than in the general population (SIR = 0.56, 95% CI: 0.42–0.73). Conclusion: The present study showed no significant linear trend between 2010 and 2015 in the incidence rates of the three cancers explored in the PLWH study sample. Specific recommendations for ICC screening are still required for HIV-infected women and should focus on sub-populations at greatest risk. [ABSTRACT FROM AUTHOR]